The most common treatment-related adverse events (TRAEs) for the AR and bevacizumab combination included elevated ALT/AST levels, thrombocytopenia, fatigue, and neuropathy, whereas for the bevacizumab and paclitaxel combination, the most common TRAEs were anemia, neutropenia, epistaxis, and fatigue [85]. This evidence concerns the gene GPT and Thrombocytopenia.